Ranbaxy Labs gained by 1% at Rs 440 on reports that its wholly-owned subsidiary -- Ranbaxy Pharmaceuticals has launched an authorised generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin.
Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.
In intra-day deals, the stock opened at Rs 441.95 and touched the high of Rs 444.10. The counter has seen trades around 69,637 shares so far on the BSE.
